# US 2026/0108554 A1 · Methods for reprogramming and gene editing cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0108554 A1
- Document ID: US20260108554A1
- Status: Published application
- Kind: A1
- Application number: 18/861,162
- Filed: 2023-05-01
- Published: 2026-04-23
- Earliest claimed: 2022-05-01
- Assignees: Factor Bioscience Inc.
- Applicants: Factor Bioscience Inc.
- Inventors: Matthew ANGEL; Christopher ROHDE; Ian HAY; Ismet Caglar TANRIKULU; Tae Yun KIM; Abigail BLATCHFORD; Mackenzie PARMENTER
- Web page: https://patentgrep.com/patent/US20260108554A1

## CPC

- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61P 35/00: Antineoplastic agents
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- C07K 14/5418: {IL-7}
- C07K 14/5428: {IL-10}
- C07K 14/5434: {IL-12}
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/625: {containing a sequence coding for a signal sequence}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12N 15/907: {in mammalian cells}
- A61K 40/00: Cellular immunotherapy (medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 2239/13: Antibody-based
- C07K 2319/02: containing a signal sequence
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2506/02: from embryonic cells
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides improved methods for reprogramming and gene editing cells, including manufacturing a population of cells comprising cells of the lymphoid lineage and/or cells of the myeloid lineage.

## Claims

### Claim at position 1

-59. (canceled)

### Claim 60

A method of engineering a cell, the method comprising
(a) contacting a cell with a synthetic RNA encoding a gene-editing protein, wherein the gene-editing protein generates a break in a target site of a beta-2-microglobulin (B2M) gene, and
(b) delivering to the cell a repair template comprising a nucleic acid sequence, wherein the nucleic acid sequence encodes an HLA-E polypeptide, wherein the nucleic acid sequence is inserted at the break in the target site of the B2M gene,
thereby generating an engineered cell.

### Claim 61 (depends on 60)

The method of claim 60, wherein the nucleic acid sequence encodes a fusion polypeptide comprising the HLA-E polypeptide and a B2M polypeptide.

### Claim 62 (depends on 61)

The method of claim 61, wherein the repair template comprises a nucleic acid sequence encoding a signal peptide.

### Claim 63 (depends on 60)

The method of claim 60, wherein the break is a double strand break.

### Claim 64 (depends on 60)

The method of claim 60, wherein the target site of the B2M gene comprises a sequence of SEQ ID NO: 12.

### Claim 65 (depends on 60)

The method of claim 60, wherein the target site of the B2M gene is in Exon 1 of the B2M gene.

### Claim 66 (depends on 60)

The method of claim 60, wherein the cell is an immune cell selected from the group consisting of a Natural Killer (NK) cell, a Natural Killer T (NKT) cell, a T cell, or a macrophage.

### Claim 67 (depends on 60)

The method of claim 60, wherein the cell is a stem cell.

### Claim 68 (depends on 67)

The method of claim 67, wherein the method further comprises generating the stem cell from a somatic cell.

### Claim 69 (depends on 60)

The method of claim 60, wherein the method results in reduced surface expression of HLA-A, HLA-B, or HLA-C by the engineered cell.

### Claim 70 (depends on 60)

The method of claim 60, wherein the method further comprises (c) contacting the cell with a nucleic acid sequence encoding a chimeric antigen receptor (CAR).

### Claim 71 (depends on 60)

The method of claim 60, wherein the cell is further engineered to express a cytokine.

### Claim 72 (depends on 71)

The method of claim 71, wherein the cytokine is selected from the group consisting of Interleukin (IL)-2, IL-15, IL-12, IL-7, IL-10, and IL-21.

### Claim 73 (depends on 60)

The method of claim 60, wherein the gene-editing protein is selected from the group consisting of a transcription activator-like (TAL) effector nuclease, RiboSlice, a zinc-finger nuclease, a meganuclease, a nickase, or a clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein.

### Claim 74 (depends on 60)

The method of claim 60, wherein the synthetic RNA comprises one or more non-canonical nucleotides.

### Claim 75 (depends on 74)

The method of claim 74, wherein the one or more non-canonical nucleotides comprise one or more of 5-hydroxycytidine, 5-methylcytidine, 5-hydroxymethylcytidine, 5-carboxycytidine, 5-formylcytidine, 5-methoxycytidine, pseudouridine, 5-hydroxyuridine, 5-methyluridine, 5-hydroxymethyluridine, 5-carboxyuridine, 5-formyluridine, 5-methoxyuridine, 5-hydroxypseudouridine, 5-methylpseudouridine, 5-hydroxymethylpseudouridine, 5-carboxypseudouridine, 5-formylpseudouridine, and 5-methoxypseudouridine.

### Claim 76 (depends on 60)

The method of claim 60, wherein the synthetic RNA, the repair template, or both the synthetic RNA and the repair template are delivered to the cell in combination with a lipid system.

### Claim 77 (depends on 76)

The method of claim 76, wherein the lipid system comprises a compound of Formula (IV):
wherein n is an integer from 1 to 15.

### Claim 78 (depends on 77)

The method of claim 77, wherein n is 4.

### Claim 79

An engineered cell comprising a disruption in a B2M gene, wherein the engineered cell expresses a fusion protein comprising a fragment of a B2M polypeptide and a HLA-E polypeptide.
